BACKGROUND: Tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS) is emerging as an important early complication of combination antiretroviral therapy in patients with TB in developing countries. The differential diagnosis of TB IRIS includes deterioration caused by other human immunodeficiency virus-related morbidities and drug-resistant TB. METHODS: We prospectively evaluated consecutive patients with suspected TB IRIS from February 2005 through July 2006 at a community-based secondary hospital in Cape Town, South Africa, by means of clinical case definitions for TB IRIS. Specimens were sent for TB culture and susceptibility testing, and a rapid test (FASTplaque-Response) was performed to expedite determination of rifampin susceptibility. RESULTS: One hundred patients with suspected TB IRIS were evaluated, 26 of whom were being retreated for TB. IRIS symptoms developed a median of 14 days (interquartile range, 7-25 days) after the initiation of combination antiretroviral therapy. In 7 patients, an alternative opportunistic disease was diagnosed. Rifampin-resistant TB was present in 13 patients, 9 of whom received a diagnosis after study entry (7 of 9 had multidrug-resistant TB). Undiagnosed rifampin-resistant TB was thus present in 10.1% of patients (95% confidence interval, 3.9%-16.4%) who presented with TB IRIS, once those with alternative diagnoses and TB with known rifampin resistance were excluded. In the remaining 80 patients, TB IRIS without rifampin resistance was the final diagnosis. CONCLUSIONS: TB IRIS that is clinically indistinguishable from TB IRIS that occurs in the context of drug-susceptible disease may occur in patients with undiagnosed multidrug-resistant TB. Antitubercular drug resistance should be excluded in all cases of suspected TB IRIS, and corticosteroids should be used with caution for patients with presumed TB IRIS until the result of drug-susceptibility testing is known.
BACKGROUND: Tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS) is emerging as an important early complication of combination antiretroviral therapy in patients with TB in developing countries. The differential diagnosis of TB IRIS includes deterioration caused by other human immunodeficiency virus-related morbidities and drug-resistant TB. METHODS: We prospectively evaluated consecutive patients with suspected TB IRIS from February 2005 through July 2006 at a community-based secondary hospital in Cape Town, South Africa, by means of clinical case definitions for TB IRIS. Specimens were sent for TB culture and susceptibility testing, and a rapid test (FASTplaque-Response) was performed to expedite determination of rifampin susceptibility. RESULTS: One hundred patients with suspected TB IRIS were evaluated, 26 of whom were being retreated for TB. IRIS symptoms developed a median of 14 days (interquartile range, 7-25 days) after the initiation of combination antiretroviral therapy. In 7 patients, an alternative opportunistic disease was diagnosed. Rifampin-resistant TB was present in 13 patients, 9 of whom received a diagnosis after study entry (7 of 9 had multidrug-resistant TB). Undiagnosed rifampin-resistant TB was thus present in 10.1% of patients (95% confidence interval, 3.9%-16.4%) who presented with TB IRIS, once those with alternative diagnoses and TB with known rifampin resistance were excluded. In the remaining 80 patients, TB IRIS without rifampin resistance was the final diagnosis. CONCLUSIONS: TB IRIS that is clinically indistinguishable from TB IRIS that occurs in the context of drug-susceptible disease may occur in patients with undiagnosed multidrug-resistant TB. Antitubercular drug resistance should be excluded in all cases of suspected TB IRIS, and corticosteroids should be used with caution for patients with presumed TB IRIS until the result of drug-susceptibility testing is known.
Authors: Marinus Barnard; Heidi Albert; Gerrit Coetzee; Richard O'Brien; Marlein E Bosman Journal: Am J Respir Crit Care Med Date: 2008-01-17 Impact factor: 21.405
Authors: Vivian Kawai; Giselle Soto; Robert H Gilman; Christian T Bautista; Luz Caviedes; Luz Huaroto; Eduardo Ticona; Jaime Ortiz; Marco Tovar; Victor Chavez; Richard Rodriguez; A Roderick Escombe; Carlton A Evans Journal: Am J Trop Med Hyg Date: 2006-12 Impact factor: 2.345
Authors: Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith Journal: Antimicrob Agents Chemother Date: 2006-04 Impact factor: 5.191
Authors: M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione Journal: JAMA Date: 2000-05-17 Impact factor: 56.272
Authors: Guy E Thwaites; Duc Bang Nguyen; Huy Dung Nguyen; Thi Quy Hoang; Thi Tuong Oanh Do; Thi Cam Thoa Nguyen; Quang Hien Nguyen; Tri Thuc Nguyen; Ngoc Hai Nguyen; Thi Ngoc Lan Nguyen; Ngoc Lan Nguyen; Hong Duc Nguyen; Ngoc Tuan Vu; Huu Hiep Cao; Thi Hong Chau Tran; Phuong Mai Pham; Thi Dung Nguyen; Kasia Stepniewska; Nicholas J White; Tinh Hien Tran; Jeremy J Farrar Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: Charles D Wells; J Peter Cegielski; Lisa J Nelson; Kayla F Laserson; Timothy H Holtz; Alyssa Finlay; Kenneth G Castro; Karin Weyer Journal: J Infect Dis Date: 2007-08-15 Impact factor: 5.226
Authors: Alison M Elliott; Henry Luzze; Maria A Quigley; Jessica S Nakiyingi; Steven Kyaligonza; Proscovia B Namujju; Constance Ducar; Jerrold J Ellner; James A G Whitworth; Roy Mugerwa; John L Johnson; Alphonse Okwera Journal: J Infect Dis Date: 2004-07-29 Impact factor: 5.226
Authors: Asha Anandaiah; Keertan Dheda; Joseph Keane; Henry Koziel; David A J Moore; Naimish R Patel Journal: Am J Respir Crit Care Med Date: 2010-12-22 Impact factor: 21.405
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988